STORM Therapeutics Ltd. (STORM), the clinical stage company pioneering cellular reprogramming through RNA modifications to treat disease, today announced a strategic collaboration with Alida ...
STORM Therapeutics has entered a new collaboration with US‑based AlidaBio to accelerate the development of cancer therapies that target RNA modifications.
SAN DIEGO, June 9, 2025 /PRNewswire/ -- Alida Biosciences, a leader in next-generation RNA modification analysis, is proud to announce its first official service provider: the Genomic and RNA ...
Science X Daily and the Weekly Email Newsletter are free features that allow you to receive your favorite sci-tech news updates in your email inbox ...
This study is led by Professor XiaoqinLiu (Peking University Institute of Advanced Agricultural Sciences, Shandong Laboratory of Advanced Agriculture Sciences, Shangdong, China). The authors explored ...
Nucleosomes are barriers to RNA Polymerase II (Pol II) transcribing along gene bodies in eukaryotes. We found that a fragile “tailless nucleosome” could be generated to resolve the Pol II pausing ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback